edkuksa/BlackFriday-GPTs-Prompts
1
0
Fork 0
mirror of https://github.com/friuns2/BlackFriday-GPTs-Prompts.git synced 2026-05-02 23:13:54 +07:00
Code Issues Packages Projects Releases Wiki Activity

2024 chatgpt update

Browse Source
This commit is contained in:
Your a
2024-05-06 10:24:52 +03:00
parent 6e6445d44a
commit c8302bf3ae
8709 changed files with 190023 additions and 18711 deletions
Download Patch File Download Diff File Expand all files Collapse all files
gpts/clinical-result-interpretation.md
+4 -2
View File
@@ -1,5 +1,5 @@
[![Clinical result interpretation](https://flow-prompt-covers.s3.us-west-1.amazonaws.com/icon/futuristic/futu_1.png)](https://gptcall.net/chat.html?data=%7B%22contact%22%3A%7B%22id%22%3A%22mybEmhcz9yGvsi_1bVTqM%22%2C%22flow%22%3Atrue%7D%7D)
# Clinical result interpretation | [Start Chat](https://gptcall.net/chat.html?data=%7B%22contact%22%3A%7B%22id%22%3A%22mybEmhcz9yGvsi_1bVTqM%22%2C%22flow%22%3Atrue%7D%7D)
Unlock the insights within your clinical data with our expert Clinical Result Interpretation.
@@ -40,6 +40,9 @@ Unlock the insights within your clinical data with our expert Clinical Result In
【Clinical conclusion】: <Write a brief conclusion based on the above content and evaluation.>
```
## Welcome Message
Unleash Your Research Power! AI Intelligent One-Click Analysis, Clinical Result Interpretation Prompt Helps You Quickly Analyze Clinical Trial Data.
## Conversation
**ASSISTANT**: 【No. of participants】: 200
@@ -152,4 +155,3 @@ Catheter-related infection 2 (15%) 0 2 (8%)© 2023 by American Society of Clinic
【Clinical conclusion】: In this phase IB study, patients with newly diagnosed PCNSL were randomized to receive either lenalidomide + R-MPV or ibrutinib + R-MPV. The treatment with lenalidomide + R-MPV resulted in 6 out of 10 evaluable patients achieving complete response/complete response unconfirmed (CR/CRu), and 4 out of 10 patients achieving partial response (PR). On the other hand, the treatment with ibrutinib + R-MPV resulted in 3 out of 11 evaluable patients achieving CR/CRu and 7 out of 11 patients achieving PR. The most common grade ≥3 treatment-related adverse events were hepatic cytolysis (38% in lenalidomide + R-MPV and 33% in ibrutinib + R-MPV) and neutropenia (23% in lenalidomide + R-MPV and 25% in ibrutinib + R-MPV). Other adverse events such as thrombocytopenia, anemia, lymphocytopenia, sepsis, and catheter-related infection were also reported. Based on these results, targeted induction immunochemotherapy with either lenalidomide + R-MPV or ibrutinib + R-MPV shows promising response rates for newly diagnosed PCNSL. Adverse events should be carefully monitored.